Vanguard Group’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $43M | Buy |
|
|||||
|
2025
Q2 | $35.1M | Buy |
|
|||||
|
2025
Q1 | $26.2M | Buy |
|
|||||
|
2024
Q4 | $31M | Buy |
|
|||||
|
2024
Q3 | $108M | Buy |
|
|||||
|
2024
Q2 | $80.3M | Buy |
|
|||||
|
2024
Q1 | $102M | Buy |
|
|||||
|
2023
Q4 | $56.9M | Buy |
|
|||||
|
2023
Q3 | $44.8M | Buy |
|
|||||
|
2023
Q2 | $47.6M | Buy |
|
|||||
|
2023
Q1 | $44.8M | Buy |
|
|||||
|
2022
Q4 | $50.2M | Buy |
|
|||||
|
2022
Q3 | $34.1M | Buy |
|
|||||
|
2022
Q2 | $21.3M | Buy |
|
|||||
|
2022
Q1 | $40.1M | Buy |
|
|||||
|
2021
Q4 | $42.9M | Buy |
|
|||||
|
2021
Q3 | $28.1M | Buy |
|
|||||
|
2021
Q2 | $28.4M | Buy |
|
|||||
|
2021
Q1 | $37.1M | Buy |
|
|||||
|
2020
Q4 | $41.8M | Buy |
|
|||||
|
2020
Q3 | $11.5M | Sell |
|
|||||
|
2020
Q2 | $11.7M | Buy |
|